Purpose
Although several studies have suggested that osteoporosis is common in survivors of gastric cancer (GC), no study to date has directly assessed the risk for osteoporosis in GC survivors compared to matched controls. Thus, we aimed to investigate the relative risk for osteoporosis in survivors of GC compared to general population.
Materials and Methods
We used the Korea National Health and Nutrition Examination Survey data (2008-2011). Patients with a history of GC (n=94) were defined as case among 8,142 individuals over 50 years old who were evaluated by dual-energy X-ray absorptiometry. Controls (n=470) were matched to cases by age and sex in a 1:5 ratio. Osteopenia (–2.5 < T-score < –1.0) and osteoporosis (T-score ≤ –2.5) were defined.
Results
The prevalence of osteoporosis in GC survivors was 30.2%, which was significantly greater than that of controls (19.7%). In total, GC survivors had a 3.7-fold increased risk for osteoporosis compared to controls (p=0.021). In addition, the risk for osteoporosis of the total proximal femur total (TF) and femur neck (FN) was significantly increased among GC survivors compared to controls (adjusted relative risk, 4.64; 95% confidence interval, 1.16 to 18.6 in TF and adjusted relative risk, 3.58; 95% confidence interval, 1.19 to 10.8 in FN). Furthermore, we found sub-optimal daily calcium intake and mean serum levels of 25-hydroxy-vitamin D in both groups.
Conclusion
GC survivors are at significantly increased risk for osteoporosis, especially in the femur. Clinically, our finding supports the importance of screening bone health and adequate nutrient supplementation in survivors of GC.
Citations
Citations to this article as recorded by
Senolytic treatment alleviates doxorubicin‐induced chemobrain Vivekananda Budamagunta, Ashok Kumar, Asha Rani, Sahana Manohar Sindhu, Yang Yang, Daohong Zhou, Thomas C. Foster Aging Cell.2024;[Epub] CrossRef
Association between Gastric Cancer and Osteoporosis: A Longitudinal Follow-Up Study Using a National Health Sample Cohort Kyeong Min Han, Mi Jung Kwon, Joo-Hee Kim, Ji Hee Kim, Woo Jin Bang, Hyo Geun Choi, Dae Myoung Yoo, Na-Eun Lee, Nan Young Kim, Ho Suk Kang Cancers.2024; 16(13): 2291. CrossRef
Preoperative abnormal bone mineral density as a prognostic indicator in patients undergoing gastrectomy for gastric cancer: A cohort study Soomin An, Wankyu Eo Medicine.2024; 103(21): e38251. CrossRef
The risk of osteoporotic fracture in gastric cancer survivors: total gastrectomy versus subtotal gastrectomy versus endoscopic treatment HyunJin Oh, Byung-Ho Yoon, Jung-Wee Park, Ye Jhin Jeon, Bit-Na Yoo, Jean Kyung Bak, Yong-Chan Ha, Young-Kyun Lee Gastric Cancer.2023; 26(5): 814. CrossRef
Factors Associated with Dietary Habit Changes in Korean Stomach Cancer Survivors after Cancer Treatment Junhee Park, Jiyoung Kim, Dong Wook Shin, Jinyoung Shin, Belong Cho, Yun-Mi Song Nutrients.2023; 15(14): 3268. CrossRef
Bone Fragility in Gastrointestinal Disorders Daniela Merlotti, Christian Mingiano, Roberto Valenti, Guido Cavati, Marco Calabrese, Filippo Pirrotta, Simone Bianciardi, Alberto Palazzuoli, Luigi Gennari International Journal of Molecular Sciences.2022; 23(5): 2713. CrossRef
Vitamin D—The Nutritional Status of Post-Gastrectomy Gastric Cancer Patients—Systematic Review Tomasz Muszyński, Karina Polak, Aleksandra Frątczak, Bartosz Miziołek, Beata Bergler-Czop, Antoni Szczepanik Nutrients.2022; 14(13): 2712. CrossRef
Bone Loss in Patients with Pancreatic Neuroendocrine Tumors He Tong, Miaomiao Wang, Jingjing Liu, Chuangen Guo, Zhongqiu Wang, Jianhua Wang, Xiao Chen Journal of Clinical Medicine.2022; 11(22): 6701. CrossRef
The risk of osteoporotic fractures after gastrectomy: Findings from the Korean national sample cohort database (2002-2019) Il Yun, Kyungduk Hurh, Sung Hoon Jeong, Eun-Cheol Park, Sung-In Jang Frontiers in Oncology.2022;[Epub] CrossRef
Incidence and risk factors of osteoporotic status in outpatients who underwent gastrectomy for gastric cancer Tsutomu Namikawa, Keiichiro Yokota, Jun Iwabu, Masaya Munekage, Sunao Uemura, Shigehiro Tsujii, Hiromichi Maeda, Hiroyuki Kitagawa, Takashi Karashima, Masamitsu Kumon, Keiji Inoue, Michiya Kobayashi, Kazuhiro Hanazaki JGH Open.2020; 4(5): 903. CrossRef
Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review) Leon Fisher, Alexander Fisher, Paul N Smith Journal of Clinical Medicine.2020; 9(10): 3253. CrossRef
Increased Risk of Osteoporotic Fracture in Postgastrectomy Gastric Cancer Survivors Compared With Matched Controls: A Nationwide Cohort Study in Korea Dong Wook Shin, Beomseok Suh, Hyunsun Lim, Yun-Suhk Suh, Yoon Jin Choi, Su-Min Jeong, Jae Moon Yun, Sun Ok Song, Youngmin Park American Journal of Gastroenterology.2019; 114(11): 1735. CrossRef
PURPOSE High-risk prostate cancer patients undergoing treatment often experience biochemical recurrence. The use of bisphosphonates as an adjuvant treatment delays skeletal events, yet whether or not bisphosphonates also delay metastastic development remains to be determined. MATERIALS AND METHODS A total of 140 high-risk prostate cancer patients who were undergoing definitive treatment and who had clinically organ-confined disease and who suffered from biochemical recurrence were administered intravenous (IV) clodronate. The patients were treated with a radical retropubic prostatectomy (RP) or curative radiotherapy (RTx). Upon androgen deprivation therapy initiation, tri-monthly IV clodronate was added to the treatment to prevent bone demineralization. Twenty-six out of 60 operated cases and 45 out of 80 irradiated cases received bisphosphonate. The length of time until the first bone metastasis was recorded and analyzed. RESULTS No statistical difference was found for the type of primary treatment (RP or RTx) on the time to the first bone metastasis (95% confidence interval [CI], 0.40 to 2.43; p=0.98). However, there was a clear advantage favoring the group that received bisphosphonate (p<0.001). The addition of bisphosphonate delayed the appearance of the first bone metastasis by seven-fold (95% CI, 3.1 to 15.4; p<0.001). CONCLUSION Treatment with tri-monthly IV clodronate delayed the time to the first bone metastasis in high-risk prostate cancer patients who were experiencing an increase in the prostate specific antigen level after definitive treatment.
Citations
Citations to this article as recorded by
Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer Xiangyu Zhang Cancer Communications.2019;[Epub] CrossRef
Bone-Targeted Therapies in Cancer-Induced Bone Disease Sofia Sousa, Philippe Clézardin Calcified Tissue International.2018; 102(2): 227. CrossRef
Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review Roderick C.N. van den Bergh, Niels J. van Casteren, Thomas van den Broeck, Eve R. Fordyce, William K.M. Gietzmann, Fiona Stewart, Steven MacLennan, Saeed Dabestani, Joaquim Bellmunt, Michel Bolla, Erik Briers, Philip Cornford, Steven Joniau, Malcolm D. Ma European Urology.2016; 69(5): 802. CrossRef
Cancer Stem Cells and Macrophages: Implications in Tumor Biology and Therapeutic Strategies Bruno Sainz, Emily Carron, Mireia Vallespinós, Heather L. Machado Mediators of Inflammation.2016; 2016: 1. CrossRef
Osteopontin is a useful predictor of bone metastasis and survival in patients with locally advanced nasopharyngeal carcinoma Xue Hou, Xuan Wu, Peiyu Huang, Jianhua Zhan, Ting Zhou, Yuxiang Ma, Tao Qin, Rongzhen Luo, Yanfen Feng, Ying Xu, Likun Chen, Li Zhang International Journal of Cancer.2015; 137(7): 1672. CrossRef
Recent advances in bone-targeted therapies of metastatic prostate cancer Xiyun Deng, Guangchun He, Junwen Liu, Feijun Luo, Xiaoning Peng, Shigang Tang, Zhiyong Gao, Qinlu Lin, Jill M. Keller, Tao Yang, Evan T. Keller Cancer Treatment Reviews.2014; 40(6): 730. CrossRef
Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer Nicole M Reusser, Heather J Dalton, Sunila Pradeep, Vianey Gonzalez-Villasana, Nicholas B Jennings, Hernan G Vasquez, Yunfei Wen, Rajesh Rupaimoole, Archana S Nagaraja, Kshipra Gharpure, Takahito Miyake, Jie Huang, Wei Hu, Gabriel Lopez-Berestein, Anil K Cancer Biology & Therapy.2014; 15(8): 1061. CrossRef
Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells R. Thaler, S. Spitzer, H. Karlic, C. Berger, K. Klaushofer, F. Varga Biochemical Pharmacology.2013; 85(2): 173. CrossRef
A new bisphosphonate derivative, CP, induces gastric cancer cell apoptosis via activation of the ERK1/2 signaling pathway Hai-jun Wang, Yu Liu, Li-qiao Fan, Cai-li Han, Ye Jiang, Shu-jie Cheng, Yong Li Acta Pharmacologica Sinica.2013; 34(12): 1535. CrossRef